Hasyim Kasim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hasyim Kasim has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Syakib Bakri
Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
9 shared publications - Haerani Rasyid
Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
7 shared publications - Arifin Seweng
Department of Biostatistics, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
6 shared publications - Akhyar Albaar
Internal Medicine Makassar South Sulawesi 90245 Hasanuddin University School of Medicine
2 shared publications - Andi Makbul Aman
Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia
2 shared publications - Nu’mAn As Daud
Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
2 shared publications
Latest Publications
- 20 September 2024
- Published by Termedia Sp. z.o.o. in HIV & AIDS Review
- Vol. 23 (3) , 217-225
Factors affecting hematological abnormality in HIV-infected patients at Dr. Wahidin Sudirohusodo Hospital Makassar, Indonesia
Introduction: Human immunodeficiency virus (HIV) is characterized by a progressive damage of immune system, resulting in a number of opportunistic infections and hematological abnormalities, and become more severe in late stages. Hematological abnormalities are common manifestations, with...
- 20 September 2024
- Published by Termedia Sp. z.o.o. in HIV & AIDS Review
- Vol. 23 (3) , 217-225
Factors affecting hematological abnormality in HIV-infected patients at Dr. Wahidin Sudirohusodo Hospital Makassar, Indonesia
Introduction: Human immunodeficiency virus (HIV) is characterized by a progressive damage of immune system, resulting in a number of opportunistic infections and hematological abnormalities, and become more severe in late stages. Hematological abnormalities are common manifestations, with...
- Open Access
- 4 August 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 3(83),p. 51-59
Effect of obesity and blood pressure dipping status on left ventricular mass in normotensive young adults
Despite the established links between obesity, blood pressure variability, and cardiovascular risks, the specific impact of the interaction between obesity and non-dipping blood pressure status on left ventricular mass (LVM) in normotensive individuals remains underexplored. Most studies have focused on hypertensive populations, leaving a critical gap in understanding how these factors contribute to cardiovascular changes in normotensive young adults. This study aims to address this gap by examining the combined effects of obesity and blood pressure dipping status on LVM in a normotensive cohort of young subjects. Methods: This cross-sectional study was conducted at Hasanuddin University Hospital and Central General Hospital (RSUP) Dr. Wahidin Sudirohusodo from March 2023, with a sample of 63 subjects divided into 32 dippers and 31 non-dippers. Interviews and ambulatory blood pressure monitoring (ABPM) were used to collect blood pressure data and history of hypertension. LVM measurements were obtained via echocardiography. Data were analyzed using SPSS version 25, with statistical significance set at p<0.05. Results: LVM was significantly greater in males, obese individuals, and non-dippers compared to females, non-obese individuals, and dippers (178.2±141.6 g vs. 102.68±32.1 g; 156.3±124.3 g vs. 101.39±26.02 g; 150.5±118.6 g vs. 103.5±38.4 g with p=0.029, p=0.026, p=0.037, respectively). Both non-dipping status and obesity significantly affected LVM, with odds ratios of 4.27 and 3.31, respectively (p<0.05). Non-dipping status was the dominant factor affecting LVM, with the lowest risk observed in the dipping and non-obese group (OR=1.00). Conclusion: Obesity and non-dipping blood pressure status, and their interaction, increase LVM. It is necessary to control obesity in young adults even if they are normotensive.
- 4 August 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 3(83),p. 51-59
Open AccessEffect of obesity and blood pressure dipping status on left ventricular mass in normotensive young adults
Despite the established links between obesity, blood pressure variability, and cardiovascular risks, the specific impact of the interaction between obesity and non-dipping blood pressure status on left ventricular mass (LVM) in normotensive individuals remains underexplored. Most studies have focused on hypertensive populations, leaving a critical gap in understanding how these factors contribute to cardiovascular changes in normotensive young adults. This study aims to address this gap by examining the combined effects of obesity and blood pressure dipping status on LVM in a normotensive cohort of young subjects. Methods: This cross-sectional study was conducted at Hasanuddin University Hospital and Central General Hospital (RSUP) Dr. Wahidin Sudirohusodo from March 2023, with a sample of 63 subjects divided into 32 dippers and 31 non-dippers. Interviews and ambulatory blood pressure monitoring (ABPM) were used to collect blood pressure data and history of hypertension. LVM measurements were obtained via echocardiography. Data were analyzed using SPSS version 25, with statistical significance set at p<0.05. Results: LVM was significantly greater in males, obese individuals, and non-dippers compared to females, non-obese individuals, and dippers (178.2±141.6 g vs. 102.68±32.1 g; 156.3±124.3 g vs. 101.39±26.02 g; 150.5±118.6 g vs. 103.5±38.4 g with p=0.029, p=0.026, p=0.037, respectively). Both non-dipping status and obesity significantly affected LVM, with odds ratios of 4.27 and 3.31, respectively (p<0.05). Non-dipping status was the dominant factor affecting LVM, with the lowest risk observed in the dipping and non-obese group (OR=1.00). Conclusion: Obesity and non-dipping blood pressure status, and their interaction, increase LVM. It is necessary to control obesity in young adults even if they are normotensive.
- Open Access
- 7 May 2024
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 13 (4) , e20416
Correlation of serum fibroblast growth factor-23 levels and calcium phosphate products levels in chronic kidney disease; sub analysis of chronic kidney disease-mineral and bone disorder study
Introduction: The body produces fibroblast growth factor-23 (FGF-23) to maintain normal phosphate levels when hyperphosphatemia occurs. Production of FGF-23 indirectly causes hypocalcemia. Phosphate and calcium disturbances also occur in chronic kidney disease (CKD), therefore this adaptation mechanism applies. This situation; however, only manifests in the early stages of CKD; if the estimated glomerular filtration rate (eGFR) is less than 30% of normal. This adaptation is no longer adequate and levels of calcium-phosphate (Ca×P) products and FGF-23 still rise. Objectives: In this study, the correlation between both the serum levels of FGF-23 and Ca×P products in CKD was analyzed. Patients and Methods: A cross-sectional study including 78 subjects with CKD stages 3 to 5 dialysis was conducted. Serum FGF-23 levels were determined using the enzyme-linked immunosorbent assay (ELISA) method and Ca×P product levels were calculated using the formula calcium (mg/ dL) × phosphate (mg/dL). The Kolmogorov-Smirnov test and Spearman’s test were conducted in the statistical study. If the P value is less than 0.05, the statistical findings are significant. Results: Serum FGF-23 levels and Ca×P product levels were shown to be significantly correlated. This analysis of the two correlations was independent of age and diabetes mellitus (DM). Based on stages of CKD, serum FGF-23 levels and Ca×P product levels were discovered to be significantly correlated only at stage 5 of non-dialysis. Conclusion: Increasing serum FGF-23 levels were correlated with increased Ca×P product levels, particularly in CKD stage 5 non-dialysis subjects. This correlation was independent of age and DM.
- 7 May 2024
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 13 (4) , e20416
Open AccessCorrelation of serum fibroblast growth factor-23 levels and calcium phosphate products levels in chronic kidney disease; sub analysis of chronic kidney disease-mineral and bone disorder study
Introduction: The body produces fibroblast growth factor-23 (FGF-23) to maintain normal phosphate levels when hyperphosphatemia occurs. Production of FGF-23 indirectly causes hypocalcemia. Phosphate and calcium disturbances also occur in chronic kidney disease (CKD), therefore this adaptation mechanism applies. This situation; however, only manifests in the early stages of CKD; if the estimated glomerular filtration rate (eGFR) is less than 30% of normal. This adaptation is no longer adequate and levels of calcium-phosphate (Ca×P) products and FGF-23 still rise. Objectives: In this study, the correlation between both the serum levels of FGF-23 and Ca×P products in CKD was analyzed. Patients and Methods: A cross-sectional study including 78 subjects with CKD stages 3 to 5 dialysis was conducted. Serum FGF-23 levels were determined using the enzyme-linked immunosorbent assay (ELISA) method and Ca×P product levels were calculated using the formula calcium (mg/ dL) × phosphate (mg/dL). The Kolmogorov-Smirnov test and Spearman’s test were conducted in the statistical study. If the P value is less than 0.05, the statistical findings are significant. Results: Serum FGF-23 levels and Ca×P product levels were shown to be significantly correlated. This analysis of the two correlations was independent of age and diabetes mellitus (DM). Based on stages of CKD, serum FGF-23 levels and Ca×P product levels were discovered to be significantly correlated only at stage 5 of non-dialysis. Conclusion: Increasing serum FGF-23 levels were correlated with increased Ca×P product levels, particularly in CKD stage 5 non-dialysis subjects. This correlation was independent of age and DM.
- Open Access
- 1 February 2024
- Published by DiscoverSys, Inc. in Bali Medical Journal
- Vol. 13 (1) , 662-667
Correlation Between Serum Calcium and Parathyroid Hormone in Chronic Kidney Disease Patients
Introduction: Chronic kidney disease (CKD) is commonly associated with secondary hyperparathyroidism. Elevated phosphorus concentrations and decreased synthesis of active vitamin D (calcitriol) as a direct result of impaired renal function induce a cascade of symptoms, including decreased calcium absorption and increased parathyroid hormone (PTH) secretion. This study aimed to assess the association between calcium levels and PTH levels in patients diagnosed with CKD. Methods: A cross-sectional observational study was conducted involving a cohort of 80 individuals diagnosed with CKD who met the established criteria. The statistical tests employed in this study were Pearson's correlation. Statistically significant findings are obtained from these tests when the p-value is below 0.05. Results: This study demonstrates a correlation between decreased levels of calcium in the blood and increased levels of PTH in persons with impaired kidney function. In eighty patients with CKD stages 3 to 5, regardless of dialysis status, a clear inverse correlation (-0.328, P = 0.000) was observed between parathyroid hormone and serum calcium levels. Conclusion: Patients with CKD showed a significant inverse correlation between their blood serum calcium levels and PTH levels. Hence, it is imperative to assess the concentrations of blood calcium and PTH in individuals with CKD and a glomerular filtration rate below 60 ml/min/1.73 m2.
- 1 February 2024
- Published by DiscoverSys, Inc. in Bali Medical Journal
- Vol. 13 (1) , 662-667
Open AccessCorrelation Between Serum Calcium and Parathyroid Hormone in Chronic Kidney Disease Patients
Introduction: Chronic kidney disease (CKD) is commonly associated with secondary hyperparathyroidism. Elevated phosphorus concentrations and decreased synthesis of active vitamin D (calcitriol) as a direct result of impaired renal function induce a cascade of symptoms, including decreased calcium absorption and increased parathyroid hormone (PTH) secretion. This study aimed to assess the association between calcium levels and PTH levels in patients diagnosed with CKD. Methods: A cross-sectional observational study was conducted involving a cohort of 80 individuals diagnosed with CKD who met the established criteria. The statistical tests employed in this study were Pearson's correlation. Statistically significant findings are obtained from these tests when the p-value is below 0.05. Results: This study demonstrates a correlation between decreased levels of calcium in the blood and increased levels of PTH in persons with impaired kidney function. In eighty patients with CKD stages 3 to 5, regardless of dialysis status, a clear inverse correlation (-0.328, P = 0.000) was observed between parathyroid hormone and serum calcium levels. Conclusion: Patients with CKD showed a significant inverse correlation between their blood serum calcium levels and PTH levels. Hence, it is imperative to assess the concentrations of blood calcium and PTH in individuals with CKD and a glomerular filtration rate below 60 ml/min/1.73 m2.
- Open Access
- 4 December 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 13 (1)
The correlation between serum fibroblast growth factor-23 levels and left ventricular hypertrophy in chronic kidney disease patients
Introduction: Hyperphosphatemia in chronic kidney disease (CKD) patients can stimulate the production of the fibroblast growth factor-23 (FGF-23) phosphatonin hormone, which is associated with cardiac remodeling resulting in left ventricular hypertrophy (LVH). Objectives: To determine the correlation between FGF-23 level and LVH incidence in CKD patients and establish the associated risk factors. Materials and Methods: This cross-sectional study involved 74 CKD patients who were classified as stage 3 (n=18), stage 4 (n=17), stage 3 (n=18), dialysis stage 5 (n=20), or non-dialysis stage 5 (n=19). The FGF-23 levels of the patients were measured using the ELISA (enzyme-linked immunosorbent assay) kit method, whereas a cardiologist verified LVH using an echocardiographic examination based on the LVH criteria of >95 g/m2 for females and >115 g/m2 for males. Results: A significant difference was observed in the mean FGF-23 values between the LVH and non-LVH patients (443.27±437.047 RU/mL and 172.68±185.56 RU/mL, respectively; P123.95 RU/mL had a 3.6 times greater risk of LVH compared to those with values ≤123.95 RU/mL. The LVH risk factors of gender and age, as well as hypertension, diabetes mellitus, and obesity diagnoses were not associated with LVH incidence in CKD patients. Conclusion: A significant association was found between FGF-23 level and LVH incidence in CKD patients, in which an FGF-23 level >123.95 RU/mL corresponded to a 3.6 times greater risk of LVH than those with FGF-23 levels below this value.
- 4 December 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 13 (1)
Open AccessThe correlation between serum fibroblast growth factor-23 levels and left ventricular hypertrophy in chronic kidney disease patients
Introduction: Hyperphosphatemia in chronic kidney disease (CKD) patients can stimulate the production of the fibroblast growth factor-23 (FGF-23) phosphatonin hormone, which is associated with cardiac remodeling resulting in left ventricular hypertrophy (LVH). Objectives: To determine the correlation between FGF-23 level and LVH incidence in CKD patients and establish the associated risk factors. Materials and Methods: This cross-sectional study involved 74 CKD patients who were classified as stage 3 (n=18), stage 4 (n=17), stage 3 (n=18), dialysis stage 5 (n=20), or non-dialysis stage 5 (n=19). The FGF-23 levels of the patients were measured using the ELISA (enzyme-linked immunosorbent assay) kit method, whereas a cardiologist verified LVH using an echocardiographic examination based on the LVH criteria of >95 g/m2 for females and >115 g/m2 for males. Results: A significant difference was observed in the mean FGF-23 values between the LVH and non-LVH patients (443.27±437.047 RU/mL and 172.68±185.56 RU/mL, respectively; P123.95 RU/mL had a 3.6 times greater risk of LVH compared to those with values ≤123.95 RU/mL. The LVH risk factors of gender and age, as well as hypertension, diabetes mellitus, and obesity diagnoses were not associated with LVH incidence in CKD patients. Conclusion: A significant association was found between FGF-23 level and LVH incidence in CKD patients, in which an FGF-23 level >123.95 RU/mL corresponded to a 3.6 times greater risk of LVH than those with FGF-23 levels below this value.
- Open Access
- 26 June 2022
- Published by scirea in SCIREA Journal of Clinical Medicine
Vitamin D Serum Level in Elderly: Its Association with The Incidence and Degree of Sarcopenia
- 26 June 2022
- Published by scirea in SCIREA Journal of Clinical Medicine
Open AccessVitamin D Serum Level in Elderly: Its Association with The Incidence and Degree of Sarcopenia
- Open Access
- 24 April 2022
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 13 (1) , e10446
Correlation of glomerular filtration rate and fibroblast growth factor-23 levels in chronic kidney disease; sub analysis chronic kidney disease–mineral and bone disorder study
Introduction: One of the chronic kidney disease (CKD) manifestations is mineral disorder, such as phosphate and calcium. Phosphatonin levels are regulated by the hormone phosphatonin, which the most commonly associated with CKD is fibroblast growth factor-23 (FGF-23), mainly synthesized by bone cells. The increase in FGF-23 in CKD subjects is a physiological response to stabilize phosphate levels. Several conditions can increase FGF-23 levels including age, body mass index (BMI), diabetes mellitus (DM), and hypertension. Objectives: This study aims to test the correlation between FGF-23 levels at various stages of glomerular filtration rate (GFR) in CKD. Patients and Methods: This study is observational with a cross-sectional approach conducted at Wahidin Sudirohusodo and Unhas hospitals of Makassar. Subjects are CKD patients which meet inclusion criteria. Intact serum FGF-23 levels were measured using an ELISA (enzyme-linked immunosorbent assay) kit (Immutopics). Statistical analysis was conducted using ANOVA test, Mann-Whitney U, and Spearman’s correlation tests. Statistical results are considered significant if P<0.05. Results: The research was conducted on 78 subjects with CKD stages 3, 4 and 5, which consisted of 40 men and 38 women. The correlation test showed that the lower the GFR, the higher the FGF-23 level (P0.05). Conclusion: We found that every increase in the CKD stages and decrease of GFR, would be associated with an increase in the plasma levels of FGF-23. However, FGF-23 plasma concentration had no significant correlation with age, BMI, DM, and hypertension.
- 24 April 2022
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 13 (1) , e10446
Open AccessCorrelation of glomerular filtration rate and fibroblast growth factor-23 levels in chronic kidney disease; sub analysis chronic kidney disease–mineral and bone disorder study
Introduction: One of the chronic kidney disease (CKD) manifestations is mineral disorder, such as phosphate and calcium. Phosphatonin levels are regulated by the hormone phosphatonin, which the most commonly associated with CKD is fibroblast growth factor-23 (FGF-23), mainly synthesized by bone cells. The increase in FGF-23 in CKD subjects is a physiological response to stabilize phosphate levels. Several conditions can increase FGF-23 levels including age, body mass index (BMI), diabetes mellitus (DM), and hypertension. Objectives: This study aims to test the correlation between FGF-23 levels at various stages of glomerular filtration rate (GFR) in CKD. Patients and Methods: This study is observational with a cross-sectional approach conducted at Wahidin Sudirohusodo and Unhas hospitals of Makassar. Subjects are CKD patients which meet inclusion criteria. Intact serum FGF-23 levels were measured using an ELISA (enzyme-linked immunosorbent assay) kit (Immutopics). Statistical analysis was conducted using ANOVA test, Mann-Whitney U, and Spearman’s correlation tests. Statistical results are considered significant if P<0.05. Results: The research was conducted on 78 subjects with CKD stages 3, 4 and 5, which consisted of 40 men and 38 women. The correlation test showed that the lower the GFR, the higher the FGF-23 level (P0.05). Conclusion: We found that every increase in the CKD stages and decrease of GFR, would be associated with an increase in the plasma levels of FGF-23. However, FGF-23 plasma concentration had no significant correlation with age, BMI, DM, and hypertension.
- Open Access
- 17 April 2022
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Proportions of hyperphosphatemia in different stages of chronic kidney disease
Introduction: In chronic kidney disease (CKD) patients, calcium and phosphate homeostasis disorders occur. Decreased kidney function will result in decreased phosphate excretion. In stage 3b CKD, the kidneys are no longer able to compensate for the phosphate load sufficiently and hyperphosphatemia is resulted. Objectives: This research aimed to figure out the proportions of hyperphosphatemic patients at different levels of glomerular filtration rate in CKD. Patients and Methods: An observational study with a cross-sectional approach involving 80 CKD subjects, distributed into stage 3 (n = 20), stage 4 (n = 20), stage 5 non-dialysis (n = 20) and stage 5 dialysis CKD subjects(n = 20), at Wahidin Sudirohusodo hospital and Unhas hospital, Makassar, from April through August 2021. Phosphate concentrations were measured using ELISA (enzyme-linked immunosorbent assay) kit (Immutopics). A result of the statistical test would be significant if P < 0.05. Results: The average phosphate concentrations at stage 3, stage 4, stage 5 non-dialysis and stage 5 dialysis were 4.14 ± 1.85 mg/dL, 4.17 ± 1.12 mg/dL, 6.43 ± 3.09 md/dL and 5.42 ± 3.09 mg/dL, respectively. Based on the avergae phosphate concentration by CKD stage, stage 3 was not significantly different from stage 4 (P = 0.969), however there was a significant difference between stage 3 and stage 5 non-dialysis (P = 0.004) and also between stage 4 and stage 5 non-dialysis (P = 0.005). The proportions of hyperphosphatemic patients (serum phosphate >4.5 mg/dL) with stage 3, stage 4, stage 5 non-dialysis and stage 5 dialysis CKD were 15% (n = 3), 20% (n = 4), 75% (n = 15) and 43.3% (n = 9), respectively. Conclusion: The porportion of hyperphosphatemic subjects increased with the decline in the kidney function. Dialysis process reduces phosphate levels and the proportion of patients with hyperphosphatemia.
- 17 April 2022
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Open AccessProportions of hyperphosphatemia in different stages of chronic kidney disease
Introduction: In chronic kidney disease (CKD) patients, calcium and phosphate homeostasis disorders occur. Decreased kidney function will result in decreased phosphate excretion. In stage 3b CKD, the kidneys are no longer able to compensate for the phosphate load sufficiently and hyperphosphatemia is resulted. Objectives: This research aimed to figure out the proportions of hyperphosphatemic patients at different levels of glomerular filtration rate in CKD. Patients and Methods: An observational study with a cross-sectional approach involving 80 CKD subjects, distributed into stage 3 (n = 20), stage 4 (n = 20), stage 5 non-dialysis (n = 20) and stage 5 dialysis CKD subjects(n = 20), at Wahidin Sudirohusodo hospital and Unhas hospital, Makassar, from April through August 2021. Phosphate concentrations were measured using ELISA (enzyme-linked immunosorbent assay) kit (Immutopics). A result of the statistical test would be significant if P < 0.05. Results: The average phosphate concentrations at stage 3, stage 4, stage 5 non-dialysis and stage 5 dialysis were 4.14 ± 1.85 mg/dL, 4.17 ± 1.12 mg/dL, 6.43 ± 3.09 md/dL and 5.42 ± 3.09 mg/dL, respectively. Based on the avergae phosphate concentration by CKD stage, stage 3 was not significantly different from stage 4 (P = 0.969), however there was a significant difference between stage 3 and stage 5 non-dialysis (P = 0.004) and also between stage 4 and stage 5 non-dialysis (P = 0.005). The proportions of hyperphosphatemic patients (serum phosphate >4.5 mg/dL) with stage 3, stage 4, stage 5 non-dialysis and stage 5 dialysis CKD were 15% (n = 3), 20% (n = 4), 75% (n = 15) and 43.3% (n = 9), respectively. Conclusion: The porportion of hyperphosphatemic subjects increased with the decline in the kidney function. Dialysis process reduces phosphate levels and the proportion of patients with hyperphosphatemia.
- Open Access
- 11 February 2022
- Published by Poltekkes Kemenkes Gorontalo in Journal of Experimental and Clinical Pharmacy (JECP)
- Vol. 2 (1) , 1-8
Efek Asam Askorbat Menurunkan Indeks Aterogenik dan Kadar Gula Darah Tikus (Rattus norvegicus L.) Diabetes Mellitus Induksi Aloksan
Senyawa antioksidan diketahui dapat meningkatkan indeks aterosklerosis dan sekresi insulin. Penelitian ini bertujuan untuk mengetahui peran asam askorbat sebagai pengatur aterosklerosis dan kadar gula darah pada kondisi diabetes (DM). Rancangan penelitian yang digunakan adalah penelitian eksperimental dengan menggunakan 20 ekor tikus putih jantan (Rattus norvegicus L.) dengan berat badan 180-300 g, umur 23 bulan, sebagai hewan percobaan. Setelah aklimatisasi selama satu minggu, tikus tidak diberi makan semalaman dan keesokan harinya diinduksi aloksan dengan dosis 145 mg/kg berat badan (BB). Tiga hari kemudian, darah diambil melalui vena ekor tikus untuk menguji gula darah. Indeks arteriosklerosis (AI) ditentukan dengan rumus (kolesterol HDL total)/HDL. Sebagai hewan percobaan, tikus dengan kadar glukosa darah 200 mg/dl atau lebih dipilih dan dibagi menjadi 4 kelompok yang masing-masing terdiri dari 5 ekor tikus. kelompok I pakan standar; Kelompok II mendapat diet standar majemuk dan metformin; Kelompok III diberi diet standar dan asam askorbat dan kelompok IV diberi diet standar dan kombinasi metformin dan asam askorbat. Pada awal diabetes, berat tikus dikurangi dari 240 g menjadi 220 g. Namun, setelah 2 minggu terapi asam askorbat, berat badan stabil, gula darah turun 65,57 dan 324,94 mg/dl menjadi 111,88 mg/dl, dan indeks arteriosklerosis menurun dari 0,324 menjadi 0,320.
- 11 February 2022
- Published by Poltekkes Kemenkes Gorontalo in Journal of Experimental and Clinical Pharmacy (JECP)
- Vol. 2 (1) , 1-8
Open AccessEfek Asam Askorbat Menurunkan Indeks Aterogenik dan Kadar Gula Darah Tikus (Rattus norvegicus L.) Diabetes Mellitus Induksi Aloksan
Senyawa antioksidan diketahui dapat meningkatkan indeks aterosklerosis dan sekresi insulin. Penelitian ini bertujuan untuk mengetahui peran asam askorbat sebagai pengatur aterosklerosis dan kadar gula darah pada kondisi diabetes (DM). Rancangan penelitian yang digunakan adalah penelitian eksperimental dengan menggunakan 20 ekor tikus putih jantan (Rattus norvegicus L.) dengan berat badan 180-300 g, umur 23 bulan, sebagai hewan percobaan. Setelah aklimatisasi selama satu minggu, tikus tidak diberi makan semalaman dan keesokan harinya diinduksi aloksan dengan dosis 145 mg/kg berat badan (BB). Tiga hari kemudian, darah diambil melalui vena ekor tikus untuk menguji gula darah. Indeks arteriosklerosis (AI) ditentukan dengan rumus (kolesterol HDL total)/HDL. Sebagai hewan percobaan, tikus dengan kadar glukosa darah 200 mg/dl atau lebih dipilih dan dibagi menjadi 4 kelompok yang masing-masing terdiri dari 5 ekor tikus. kelompok I pakan standar; Kelompok II mendapat diet standar majemuk dan metformin; Kelompok III diberi diet standar dan asam askorbat dan kelompok IV diberi diet standar dan kombinasi metformin dan asam askorbat. Pada awal diabetes, berat tikus dikurangi dari 240 g menjadi 220 g. Namun, setelah 2 minggu terapi asam askorbat, berat badan stabil, gula darah turun 65,57 dan 324,94 mg/dl menjadi 111,88 mg/dl, dan indeks arteriosklerosis menurun dari 0,324 menjadi 0,320.
- Open Access
- 12 February 2020
- Published by Bentham Science Publishers Ltd. in The Open Urology & Nephrology Journal
- Vol. 13 (1) , 1-4
Correlation Between Non-Alcoholic Fatty Liver and Chronic Kidney Disease
Background: NAFLD is an independent risk factor of CKD. CKD prevalences in NAFLD subjects are two times higher than non-NAFLD. The aim of this study is to know the correlation between NAFLD and CKD. Methods: Cross-sectional study was conducted on patients who held Abdominal USG in Wahidin Sudirohusodo & UNHAS hospital from January to December 2017. NAFLD subjects are male and female (18-60 years) who met NAFLD criteria and wanted to participate, non-NAFLD as control subjects. NAFLD is fat accumulation in hepatocyte without a history of alcohol consumption or other etiology of chronic liver disease. CKD definition and classification were based on KDIGO 2012. P value <0.05 was considered to be significant. Results: From the study period, we found 134 subjects (67 NAFLD subjects and 67 non-NAFLD subjects). Correlation analysis between NAFLD and eGFR showed that NAFLD subjects had more proportion of eGFR <60 ml/min/1.73m 2 than non-NAFLD subjects (40.3% vs 16.4%, p=0.002). NAFLD subjects significantly had more proportion of CKD Grade 3 than non-NAFLD subjects (37.3% vs 9%) while non-NAFLD subjects had more proportion of CKD Grade 1 and 2 than NAFLD subjects (56.7% vs 38.8% dan 26.9% vs 20.9%)(p=0.001). Correlation analysis between NAFLD and proteinuria did not show significant results (p=0.051). Conclusion: NAFLD subjects correlated with CKD events compared with non-NAFLD subjects.
- 12 February 2020
- Published by Bentham Science Publishers Ltd. in The Open Urology & Nephrology Journal
- Vol. 13 (1) , 1-4
Open AccessCorrelation Between Non-Alcoholic Fatty Liver and Chronic Kidney Disease
Background: NAFLD is an independent risk factor of CKD. CKD prevalences in NAFLD subjects are two times higher than non-NAFLD. The aim of this study is to know the correlation between NAFLD and CKD. Methods: Cross-sectional study was conducted on patients who held Abdominal USG in Wahidin Sudirohusodo & UNHAS hospital from January to December 2017. NAFLD subjects are male and female (18-60 years) who met NAFLD criteria and wanted to participate, non-NAFLD as control subjects. NAFLD is fat accumulation in hepatocyte without a history of alcohol consumption or other etiology of chronic liver disease. CKD definition and classification were based on KDIGO 2012. P value <0.05 was considered to be significant. Results: From the study period, we found 134 subjects (67 NAFLD subjects and 67 non-NAFLD subjects). Correlation analysis between NAFLD and eGFR showed that NAFLD subjects had more proportion of eGFR <60 ml/min/1.73m 2 than non-NAFLD subjects (40.3% vs 16.4%, p=0.002). NAFLD subjects significantly had more proportion of CKD Grade 3 than non-NAFLD subjects (37.3% vs 9%) while non-NAFLD subjects had more proportion of CKD Grade 1 and 2 than NAFLD subjects (56.7% vs 38.8% dan 26.9% vs 20.9%)(p=0.001). Correlation analysis between NAFLD and proteinuria did not show significant results (p=0.051). Conclusion: NAFLD subjects correlated with CKD events compared with non-NAFLD subjects.